San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor in the weight loss drug sector in February right after revealing promising data from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injection As well as in Mar